MMAIC-IPMN: Multimodal models, liquid biopsy, and artificial cohorts as tools for risk-adjusted surveillance of precancerous pancreatic lesions

The aim of the MMAIC-IPMN research project is to develop a risk score that can identify the likelihood of developing pancreatic cancer and communicate it as early as possible to people diagnosed with IPMN (intraductal papillary mucinous neoplasm, cystic lesion of the pancreas). Thus, the development of pancreatic cancer can be prevented as much as possible through early screening.

The "Patient Participation" subproject addresses existing calls for more participatory research. For patient participation, N=10-15 affected individuals and N=5 close relatives will be included as patient representatives. Affected individuals are people diagnosed with IPMN. Qualitative methods will be used, including individual and group discussions and workshops. For example, the topic of openness to novel molecular diagnostic blood tests will be discussed. A generally understandable explanation of the risk score will also be developed jointly.